Table 1 Baseline demographic and clinical characteristics of patients in the derivation set and the validation set

Demographics

 Age (years)^a

56(48, 65)

58(49, 65)

0.075

 Male sex, n (%)

402(76.9)

185(82.2)

0.102

 Smoker, n (%)

161(30.8)

73(32.4)

0.653

 Drinker, n (%)

136(26.0)

56(24.9)

0.749

 BMI (kg/m2) ^a

26.1(24.3, 28.7)

26.0(24.2, 28.4)

0.483

 SBP, mmHg

129(120, 138)

132(120, 141)

0.181

 DBP, mmHg

77(70, 84)

77(70, 84)

0.997

Comorbidities, n (%)

 Hypertension

305(58.3)

146(64.9)

0.092

 Hyperlipemia

475(90.8)

210(93.3)

0.257

 T2DM

163(31.2)

85(37.8)

0.078

 Hyperuricemia

22(4.2)

11(4.9)

0.677

 Prior MI

80(15.3)

28(12.4)

0.309

 Prior cerebral infarction

48(9.2)

11(4.9)

0.046

Laboratory examination s at admission^a

 eGFR (mL/min)

93.9(85.8, 102.1)

93.9(82.8, 100.7)

0.208

 SCr (μmol/L)

76.4(68.2, 84.9)

76.4(70.7, 86.4)

0.182

 UA (μmol/L)

347.1(298.4, 402.1)

347.1(302.3, 392.3)

0.551

 PLT (*10⁹/L)

219(195, 246)

219(188, 249)

0.646

 ALT (U/L)

20(15, 28)

20(17, 29)

0.121

 AST (U/L)

19(16, 23)

19(17, 24)

0.089

 TG (mmol/L)

1.55(1.21, 2.18)

1.54(1.19, 1.99)

0.224

 TC (mmol/L)

4.26(3.45, 5.24)

4.26(3.60, 4.94)

0.826

 HDL-C (mmol/L)

1.02(0.89, 1.18)

1.02(0.91, 1.16)

0.567

 LDL-C (mmol/L)

2.41(1.77, 3.20)

2.41(1.91, 3.02)

0.982

Concomitant medication, n (%)

 Statins

508(97.1)

219(97.3)

0.878

 Ezetimibe

129(24.7)

54(24.0)

0.846